Amneal Pharmaceuticals Gestione
Criteri Gestione verificati 4/4
Amneal Pharmaceuticals Il CEO è Chirag Patel, nominato in Jan2005, e ha un mandato di 21.42 anni. la retribuzione annua totale è $ 8.69M, composta da 9.2% di stipendio e 90.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 7.1% delle azioni della società, per un valore di $ 367.14M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.9 anni e 7.5 anni.
Informazioni chiave
Chirag Patel
Amministratore delegato
US$8.7m
Compenso totale
| Percentuale dello stipendio del CEO | 9.20% |
| Mandato del CEO | 21.4yrs |
| Proprietà del CEO | 7.1% |
| Durata media del management | 6.9yrs |
| Durata media del Consiglio di amministrazione | 7.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 04
AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound
Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.Aggiornamento della narrazione • May 04
AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback
Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.Seeking Alpha • Apr 21
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
Summary Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positive FY26 guidance and outperformance of Crexont and Brekiya drugs supporting the growth thesis. Despite negative equity and below-investment grade credit, AMRX's 15.2% operating cash flow growth and undervaluation versus peers helps support a bullish outlook. Key risks include drug trial failures, regulatory setbacks, and litigation, but AMRX's pipeline diversification and macro tailwinds across clinical areas bolster its medium-to-long-term potential. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 19
AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.Aggiornamento della narrazione • Apr 02
AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup
Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.Aggiornamento della narrazione • Mar 18
AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback
Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.Aggiornamento della narrazione • Mar 04
AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup
Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.Aggiornamento della narrazione • Feb 17
AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup
Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.Aggiornamento della narrazione • Feb 03
AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook
Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.Aggiornamento della narrazione • Jan 19
AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook
Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.Aggiornamento della narrazione • Jan 05
AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.Aggiornamento della narrazione • Dec 13
AMRX: Complex Generics Approvals Will Support Future Earnings Upside
Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.Articolo di analisi • Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...Aggiornamento della narrazione • Nov 29
AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook
Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.Aggiornamento della narrazione • Nov 15
AMRX: Sustained Outperformance Will Drive Future Earnings Confidence
Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.Articolo di analisi • Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...Aggiornamento della narrazione • Nov 01
AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum
Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.Aggiornamento della narrazione • Sep 17
Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.Articolo di analisi • Aug 08
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a good week for Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shareholders, because the company has just...Articolo di analisi • Jul 24
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S
With a price-to-sales (or "P/S") ratio of 0.9x Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) may be sending very bullish...
Nuova narrazione • Mar 22
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.Seeking Alpha • Mar 19
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Summary Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. Key growth areas include biosimilars, specialty drugs like CREXONT, and the high-growth GLP-1 weight loss market, positioning AMRX stock for long-term success. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$122m |
| Dec 31 2025 | US$9m | US$800k | US$72m |
| Sep 30 2025 | n/a | n/a | US$6m |
| Jun 30 2025 | n/a | n/a | US$3m |
| Mar 31 2025 | n/a | n/a | -US$13m |
| Dec 31 2024 | US$7m | US$788k | -US$117m |
| Sep 30 2024 | n/a | n/a | -US$184m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
Compensazione vs Mercato: La retribuzione totale di Chirag ($USD 8.69M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.38M ).
Compensazione vs guadagni: La retribuzione di Chirag è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Chirag Patel (59 yo)
21.4yrs
Mandato
US$8,691,745
Compensazione
Mr. Chirag K. Patel is Managing Trustee of Liberty Science Center, Inc. He is Co-Founder & Executive Chairman of Kashiv BioSciences, LLC. Mr. Patel has been Co-Chief Executive Officer, President and Direct...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | US$8.69m | 7.1% $ 367.1m | |
| Co-Founder | 24.4yrs | US$8.73m | 8.19% $ 423.5m | |
| Executive VP & CFO | 6.3yrs | US$3.29m | 0.14% $ 7.3m | |
| Executive VP | 4.4yrs | US$2.86m | 0.079% $ 4.1m | |
| Executive VP & Chief Human Resources Officer | 12.4yrs | US$2.73m | 0.13% $ 6.5m | |
| Executive VP and Chief Commercial Officer of Generics & Biosciences | 8.3yrs | US$3.02m | 0.13% $ 6.9m | |
| Head/VP of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Corporate Development | 3.4yrs | Nessun dato | Nessun dato | |
| Senior VP of Strategic Sourcing & Supply Management | 3.4yrs | Nessun dato | Nessun dato | |
| Chief Quality Officer | 7.4yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Scientific Officer of Generics | 6.4yrs | Nessun dato | Nessun dato | |
| Vice President & Head of Medical Affairs | no data | Nessun dato | Nessun dato |
6.9yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di AMRX è esperto e expertise (durata media dell'incarico 6.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | US$8.69m | 7.1% $ 367.1m | |
| Co-Founder | 24.4yrs | US$8.73m | 8.19% $ 423.5m | |
| Independent Chairman of the Board | 6.8yrs | US$472.63k | 0.26% $ 13.5m | |
| Independent Director | 8.1yrs | US$393.33k | 0.11% $ 5.5m | |
| Independent Director | 8.1yrs | US$401.03k | 0.10% $ 5.3m | |
| Independent Director | 6.5yrs | US$386.59k | 0.10% $ 5.2m | |
| Independent Director | 6.5yrs | US$413.91k | 0.11% $ 5.6m | |
| Director | 8.1yrs | US$363.61k | 0.52% $ 26.6m | |
| Independent Director | 3.9yrs | US$365.00k | 0.029% $ 1.5m | |
| Independent Director | 6.5yrs | US$434.59k | 0.082% $ 4.2m |
7.5yrs
Durata media
63yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMRX sono considerati esperti (durata media dell'incarico 7.5 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/15 18:18 |
| Prezzo dell'azione a fine giornata | 2026/06/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Amneal Pharmaceuticals, Inc. è coperta da 20 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |